Welcome to our dedicated page for AUNA S.A. news (Ticker: AUNA), a resource for investors and traders seeking the latest updates and insights on AUNA S.A. stock.
Auna S.A. reports developments for a Latin American healthcare platform operating in Mexico, Peru and Colombia. The company combines a network of hospitals, ambulatory centers, prevention and wellness facilities with oncology and selected general health plans, with segment reporting around Oncosalud Peru and healthcare services in Peru, Colombia and Mexico.
Recurring news covers quarterly financial results, key performance indicators, operating trends by country, capital structure actions, debt refinancing, public-private partnership activity such as Torre Trecca in Lima, and strategic healthcare collaborations. Updates also include Form 20-F reporting dates and financial guidance tied to its integrated services-and-plans model.
Auna (NYSE:AUNA) reported 1Q26 revenue of S/1,178 million, up 10% FXN and 13% YoY. Adjusted EBITDA was S/217 million, down 5% FXN with an 18.4% margin.
Operating cash flow rose 48% YoY, organic free cash flow grew 2.6x, leverage stayed at 3.7x, and full-year 2026 revenue and Adjusted EBITDA guidance were reaffirmed.
Auna (NYSE: AUNA) announced it filed its Annual Report on Form 20-F for fiscal year ended December 31, 2025 with the SEC on April 21, 2026. The company said shareholders can access the filing on the SEC website or the company’s Investor Relations “Financial Info” page.
Shareholders may request a free hard copy of the audited financial statements or the complete 2025 Form 20-F by contacting the Investor Relations team at contact@aunainvestors.com.
Auna (NYSE: AUNA) reported preliminary operating metrics for the quarter ended March 31, 2026 across Mexico, Peru and Colombia and will publish these KPIs quarterly going forward.
Key highlights: Mexico chemotherapies/radiotherapies rose to 4,162 sessions; Peru capacity utilization was 76.3%; Colombia capacity utilization reached 79.3% and protected lives tracked at 3,057,763.
Auna (NYSE: AUNA) announced the schedule for its First Quarter 2026 financial results. Earnings release: Tuesday, May 19, 2026 (after market close). Conference call: Wednesday, May 20, 2026 at 8:00 a.m. ET. Quiet period: May 4–19, 2026. Dial-in and webcast details provided for investor participation.
Auna (NYSE: AUNA) reported FY25 revenue of S/4,385 million (flat reported; +4% FXN) and Adjusted EBITDA of S/917 million (down 3% FXN; margin 20.9%). Free cash flow rose 35% YoY and Adjusted Net Income increased to S/336 million. 4Q25 revenue was S/1,133 million and Adjusted EBITDA S/220 million. The company completed a US$825 million refinancing, entered 2026 with net leverage of 3.6x, and issued 2026 guidance of ~12% FXN revenue and Adjusted EBITDA growth.
Peru and Colombia performed well; Mexico showed signs of recovery with early 2026 improvements under new local management.
Auna (NYSE:AUNA) executed an addendum to its PPP with EsSalud to begin construction of Torre Trecca, a 23-story, 59,000 m2 outpatient facility in Lima. The project is expected to increase EsSalud capacity ~20%, support >3 million annual visits, and start operations mid-2028 under a concession running to 2046 (renewable to 2064).
Construction financing is at the project level; Auna has limited upfront capital requirements and will receive predictable cash flows via EsSalud progress certificates and guaranteed minimum monthly payments once operational.
Auna (NYSE: AUNA) announced the dates and access details for its Fourth Quarter and Full-Year 2025 financial results. Earnings release: Tuesday, March 10, 2026 after market close. Conference call: Wednesday, March 11, 2026 at 8:00 a.m. ET. Quiet period: Feb 23–Mar 10, 2026.
Dial-in numbers, entry passcode 3884034, and a webcast link will be provided for participation.
Auna (NYSE: AUNA) reported 3Q25 consolidated revenue of S/1,117 million (+1% FXN, -1% YoY) and Adjusted EBITDA of S/232 million (Adjusted EBITDA margin 20.8%, down 1.3 p.p. YoY).
Adjusted Net Income was S/58 million versus S/75 million in 3Q24 and consolidated leverage remained at 3.6x Net Debt/Adjusted EBITDA. Regional performance diverged: Peru revenue +9% LC and Adjusted EBITDA +15% LC; Colombia revenue +4% LC and Adjusted EBITDA +18% LC; Mexico revenue fell 12% and Adjusted EBITDA declined 29% (Mexico affected by slower procedure demand and IT implementation issues).
Post-quarter, Auna completed a USD 765 million debt refinancing and announced strategic partnerships to support Mexico recovery and medium-term deleveraging toward below 3x.
Auna (AUNA) announced on November 20, 2025 a Memorandum of Understanding with Sojitz Corporation of America to explore joint healthcare business opportunities across Latin America, with an initial focus on Mexico.
The companies said the collaboration will combine Auna’s healthcare and operational expertise with Sojitz’s investment capabilities and international network to accelerate development of scalable healthcare infrastructure and services. Auna reiterated its prior plan to invest approximately US$500 million over the next three to five years to expand its integrated healthcare platform in Mexico.
Auna (NYSE:AUNA) announced that EsSalud has formally received the construction license for Torre Trecca, a high-rise outpatient center Auna will rebuild and operate under the existing public–private partnership.
Torre Trecca is expected to serve more than 6 million EsSalud-insured Lima residents and accommodate over 3 million visits annually. The license delivery was marked by a ceremony with EsSalud, ProInversión and local officials.
An amendment to the PPP contract is expected to receive final approval by year-end 2025, enabling construction to begin in 2026. Auna reiterated its commitment to expanding access to high-quality healthcare in Lima.